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Abstract
Advances in the treatment of bulimia nervosa and binge-eating disorder (BN/BED) have been marred by our limited
understanding of the underpinning neurobiology. Here we measured regional cerebral blood flow (rCBF) to map
resting perfusion abnormalities in women with BN/BED compared with healthy controls and investigate whether
intranasal oxytocin (OT), proposed as a potential treatment, can restore perfusion in disorder-related brain circuits.
Twenty-four women with BN/BED and 23 healthy women participated in a randomized, double-blind, crossover,
placebo-controlled study. We used arterial spin labelling MRI to measure rCBF and the effects of an acute dose of
intranasal OT (40 IU) or placebo over 18–26 min post dosing, as we have previously shown robust OT-induced changes
in resting rCBF in men in a similar time-window (15–36 min post dosing). We tested for effects of treatment, diagnosis
and their interaction on extracted rCBF values in anatomical regions-of-interest previously implicated in BN/BED by
other neuroimaging modalities, and conducted exploratory whole-brain analyses to investigate previously
unidentified brain regions. We demonstrated that women with BN/BED presented increased resting rCBF in the medial
prefrontal and orbitofrontal cortices, anterior cingulate gyrus, posterior insula and middle/inferior temporal gyri
bilaterally. Hyperperfusion in these areas specifically correlated with eating symptoms severity in patients. Our data did
not support a normalizing effect of intranasal OT on perfusion abnormalities in these patients, at least for the specific
dose (40 IU) and post-dosing interval (18–26 min) examined. Our findings enhance our understanding of resting brain
abnormalities in BN/BED and identify resting rCBF as a non-invasive potential biomarker for disease-related changes
and treatment monitoring. They also highlight the need for a comprehensive investigation of intranasal OT
pharmacodynamics in women before we can fully ascertain its therapeutic value in disorders affecting predominantly
this gender, such as BN/BED.
Introduction
Bulimia nervosa (BN) and binge-eating disorder (BED)
are psychiatric disorders characterized by recurrent binge
eating1. In BN, binge eating is accompanied by excessive
compensatory behaviours, which are absent in BED2. As
recovery rates after standard treatment remain poor in
both disorders3, developing new effective treatments that
address binge eating are needed; however, progress is
impeded by our limited understanding of the neurobiol-
ogy of BN/BED.
BN/BED have been conceptualized as impulsive/com-
pulsive eating disorders4 with altered reward sensitivity5
and food-related attentional biases6. Consistent with this
model of BN/BED, neuroimaging studies in these patients
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have highlighted changes in the function, structure and
neurochemistry in brain areas involved in incentive pro-
cessing (such as the orbitofrontal cortex (OFC), ventral
tegmental area (VTA), substantia nigra (SN), nucleus
accumbens and the amygdala), inhibitory control (such as
the medial prefrontal cortex (PFC) and the anterior cin-
gulate (ACG)) and habitual behaviour (such as the dorsal
striatum) (see refs. 7,8 for detailed reviews). Most of these
studies focused on morphological differences between
BN/BED patients and healthy controls. Some studies
investigated functional abnormalities using task-based
BOLD functional magnetic resonance imaging (fMRI),
allowing for inferences that are restricted to the neural
circuits employed by the specific tasks. Other studies
investigated alterations in spontaneous fluctuations of the
BOLD signal at rest, suggesting aberrant functional con-
nectivity in brain networks involved in salience attribu-
tion, self-referential processing and cognitive control in
people with BN/BED9–13). However, BOLD fMRI (whe-
ther focusing on fluctuations at rest or task-evoked
changes) typically yields only relative metrics and is
prone to several artefacts, including motion, low-
frequency physiological noise and baseline drift14. Three
other studies, all with small sample sizes, used single-
photon emission computerized tomography (SPECT) to
measure regional cerebral blood flow (rCBF), which pro-
vides a proxy of brain metabolism and neural activity15.
These studies reported rCBF increases in the temporal
lobes and/or the frontal cortex of patients with BN and
BED in response to anticipation or exposure to food/body
shape-related stimuli16–18. However, SPECT is a high-cost
technique that requires the injection of a radionuclide
tracer, making it suboptimal as a routine screening tool in
non-specialized centres or for evaluating short-term
responses19.
Recently, arterial spin labelling (ASL) MRI has allowed
the non-invasive quantification of rCBF with high repro-
ducibility and spatial resolution20. ASL is a quantitative
technique and has been used widely to quantify changes
in brain physiology associated with various neu-
ropsychiatric disorders21 (e.g., autism spectrum dis-
order22, schizophrenia23, depression24) and in response to
pharmacological treatments25,26. Hence, ASL provides a
non-invasive and widely available tool to investigate
abnormalities in resting brain physiology of BN/BED and
the effects of potential treatments.
One such potential treatment is intranasal oxytocin
(OT)27–29. The implication of OT in binge eating is sup-
ported by a wide range of evidence. Candidate gene studies
have found associations between polymorphisms in the
OT receptor gene and binge-purge tendencies in women
(rs53576/rs2254298)30, bulimia (rs53576)31 and overeating
(rs2268493/rs2268494)32. Similarly, Prader–Willi syn-
drome patients present with a reduction in OT-synthesizing
neurons in the paraventricular nucleus of the hypothala-
mus33, which is accompanied by compulsive overeating
behaviour from early childhood34. However, the only two
studies conducted to compare the levels of OT in the
cerebrospinal fluid of patients with BN and healthy con-
trols could not find any differences35,36. Pharmacological
animal37 and human studies38,39 have demonstrated that
OT suppresses eating, including hedonic eating in men39.
Although the exact mechanisms underlying the suppres-
sive effects of OT on eating remain to be fully uncov-
ered27,28, current understanding supports a combination
of both metabolic and cognitive effects40, including
modulation of reward-related signalling41,42. In addition,
some small clinical studies starting to explore the
potential of intranasal OT in improving disordered eating
in patients with BN have shown that intranasal OT
(40 IU) reduces caloric intake43 and decreases vigilance
towards angry faces44 in women with BN. We have
recently shown that a divided dose of intranasal OT
(64 IU) modulates risk-taking behaviour in women with
BN/BED45 and increases vigilance towards food, vs. neu-
tral, images in a dot probe task in both women with and
without BN/BED46. However, in the same cohort of
women with BN/BED, we failed to find any effect of the
same divided dose of intranasal OT (64 IU) on eating
behaviour or stress response47. Apart from the lack of
clarity regarding the effectiveness of intranasal OT to
improve eating symptomatology in patients with BN/BED,
it is also not clear which brain circuits intranasal OT
targets in BN/BED patients.
In this study, we investigate abnormalities in resting
brain physiology in women with BN/BED using ASL.
Studying the brain at rest allows us to investigate baseline
alterations in brain physiology that are not restrained to
the specific neural circuits engaged by tasks. We further
investigate whether an acute dose of 40IU of intranasal
OT can restore alterations in resting brain physiology in
BN/BED 18–26min post dosing. We have previously
shown that ASL captures OT-induced changes as early as
15–36 min post dosing in resting rCBF after a single acute
intranasal administration (40 IU) in both healthy men48,49
and men at clinical high-risk for psychosis (CHR-P)50
(earlier time intervals have simply never been studied).
We specifically address two questions: (1) Do women with
BN/BED, compared with healthy women, present altera-
tions in resting brain perfusion, as measured using ASL
MRI? (2) Can 40 IU intranasal OT restore or attenuate
these resting rCBF alterations in women with BN/BED
18–26 min post doing?
Methods
Participants
We recruited 25 women meeting the DSM-5 criteria for
either BN (n= 20) or BED (n= 5) and 27 women with no
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current or prior eating disorder. We excluded three par-
ticipants (two healthy controls and one BN patient) due to
a large discrepancy in the time post dosing that we
sampled rCBF in the OT and placebo visits (it exceeded
the duration of one rCBF scan, i.e., >8 min). We further
excluded two healthy women due to corruption of the
data files. Our final sample included 23 healthy and 24
women with BN/BED. Ethical approval for the study was
granted by the London—Camberwell St Giles Research
Ethics Committee (Reference: 14/LO/2115). All partici-
pants provided written informed consent and participated
voluntarily. See Supplementary Materials for further
details regarding inclusion/exclusion criteria. Our pre-
vious work has demonstrated that n= 16 per group is
sufficient to quantify OT-induced rCBF changes in men
using a between-subjects49 or within-subjects design48.
Study design and procedure
We employed a double-blind, placebo-controlled
crossover design. Participants visited our centre on three
occasions: one screening and two experimental visits.
During screening, we measured height, weight, and col-
lected basic demographics. Participants then completed
the Eating Disorder Examination—Questionnaire (EDEQ)
Version51 and Depression, Anxiety, and Stress Scales52
online in their own time between the screening and the
first experiment visits, to minimize burden during the
visits. Both questionnaires have been validated for online
application, with online responses matching well the
responses of participants in the controlled environment of
the lab53,54. To habituate all participants to the scanner
environment and minimize its potential distressing
impact, all participants were first trained in a mock-
scanner.
The experimental visits were conducted 2 days apart,
ensuring participants were tested in the same phase of the
oestrous cycle for both treatment conditions (OT and
placebo). Each participant was asked to report the first day
of their last menstrual period and any hormonal contra-
ception they were currently taking. Participants were
asked to eat 2.5 h prior to each experimental visit, to
control for baseline hunger. All participants were tested at
approximately the same time in the early evening
(5–7 pm) for both the OT and placebo treatments, to
minimize potential circadian variability in resting brain
activity55 or OT levels56. Fifty minutes after arrival, par-
ticipants self-administered 40 IU intranasal OT (Syntoci-
non, 40 IU/ml; Novartis, Basel, Switzerland) in ten puffs,
one puff every 30 s, each puff containing 0.1 ml Syntoci-
non (4 IU) or placebo (same excipients as Syntocinon
except for OT) and alternating between nostrils, over a
period of 5 min. Participants were randomly allocated to a
treatment order (OT/placebo or placebo/OT). After drug
administration, participants were guided to the MRI
scanner, where a single pulsed continuous ASL scan
(8:20 min) was acquired 18–26 min (±4mins) post dosing.
Our choice of OT dose and post dosing interval was
driven by our previous work, whereby we have shown that
40 IU intranasal OT induce robust changes in rCBF in
both healthy men (as early as 15–32min post dosing)48,49
and men at CHR-P (at 22–36 min)50. Furthermore, pre-
vious clinical studies have shown beneficial effects of a
dose of 40 IU intranasal OT in women with BN43,44.
MRI data acquisition
We used a three-dimensional (3D) pseudo-continuous
ASL (3D-pCASL) sequence to measure changes in rCBF
over 18–26min post dosing. Participants were instructed
to lie still, maintain their gaze on a centrally placed fixa-
tion cross during scanning and to let their mind flow (as
per current practice for the acquisition of open-eyes
resting-state data57). Labelling of arterial blood was
achieved with a 1825ms train of Hanning-shaped RF
pulses in the presence of a net magnetic field gradient
along the flow direction (the z-axis of the magnet). After a
post-labelling delay of 2025ms, a whole-brain volume was
read using a 3D interleaved “stack-of-spirals” Fast Spin
Echo readout58, consisting of 8 interleaved spiral arms in
the in-plane direction, with 512 points per spiral inter-
leave. Echo time (TE) was 11.088ms and repetition time
(TR) was 5135ms. Fifty-six slice partitions of 3 mm
thickness were defined in the 3D readout. The in-plane
field of view (FOV) was 240 × 240 mm. The spiral sam-
pling of k-space was re-gridded to a rectangular matrix
with an approximate in-plane resolution of 3.6 mm. Each
sequence used five control-label (C-L) pairs. Individual
CBF maps were computed for each of the perfusion
weighted difference images derived from every C-L pair,
by scaling the difference images against a proton density
image acquired at the end of the sequence, using identical
readout parameters. This computation was done accord-
ing to the formula suggested in the recent ASL consensus
article59. The sequence uses four background suppression
pulses to minimize static tissue signal at the time of image
acquisition. We acquired eight 3D-pCASL sequences,
with the duration of the entire acquisition time of each
sequence being 8:20 min.
A 3D high-spatial-resolution, magnetization prepared
rapid acquisition T1-weighted scan was also acquired
(FOV of 270mm, TR/TE/TI= 7.328/3.024/400 ms). The
final resolution of the T1-weighted image was 1.1 × 1.1 ×
1.2 mm.
MRI data pre-processing
A multi-step approach was performed for the spatial
normalization of the CBF maps to Montreal Neurological
Institute (MNI) space: (1) co-registration of the proton
density image from each sequence to the participant’s
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T1 image after resetting the origin of both images to the
anterior commissure. The transformation matrix of this
co-registration step was then applied to the CBF map, to
transform the CBF map to the space of the T1-image; (2)
unified segmentation of the T1 image; (3) elimination of
extra-cerebral signal from the CBF map, by multi-
plication of the “brain only” binary mask obtained in step
(2), with each co-registered CBF map; (4) normalization
of the subject’s T1 image and the skull-stripped CBF
maps to the MNI152 space using the normalization
parameters obtained in step (2). Finally, we spatially
smoothed each normalized CBF map using an 8 mm
Gaussian smoothing kernel. All of these steps were
implemented using the ASAP (Automatic Software for
ASL processing) toolbox (version 2.0)60. The resulting
smoothed CBF maps were then entered into Statistical
Parametric Mapping (SPM) 12 (http://www.fil.ion.ucl.ac.
uk/spm/software/spm12/) for group-level statistical
analysis, as described below.
Statistical analyses
Diagnosis, treatment and diagnosis × treatment effects on
resting rCBF
To investigate the effects of diagnosis and treatment on
global CBF, we first extracted mean global CBF values
with an explicit binary mask for grey matter using the
fslmeants command (FSL suite, http://www.fmrib.ox.a.c.
uk/fsl). The binary mask was derived from a standard T1-
based probabilistic map of grey-matter distribution by
thresholding all voxels with a probability > 0.20. We tested
for the main effects of treatment or diagnosis and for the
treatment × diagnosis interaction on global grey-matter
CBF signal using mixed analysis of variance and the
Greenhouse-Geisser correction against violations of
sphericity.
We then tested the effects of diagnosis, treatment and
diagnosis × treatment on mean rCBF values extracted
using fslmeants from 14 regions-of-interest (ROIs) cor-
responding to anatomical areas shown to be affected in
BN/BED in previous structural, functional or neuro-
chemical studies7,8. A detailed description of these ROIs
can be found in Supplementary Fig. S1. The VTA, SN and
hypothalamus masks were retrieved from a recently
published high-resolution probabilistic atlas of human
subcortical brain nuclei61. The OFC mask included the
areas 14 and 11m, and the medial PFC included area FPm
from the connectivity-based parcellation map in Franz-
Xaver Neubert et al.62. All the remaining masks were
retrieved from the Harvard-Oxford Atlas distributed with
FSL. To create the dorsal striatum masks, we pooled
together in one single mask the caudate and putamen
masks from the Harvard-Oxford Atlas. For the insula,
amygdala, accumbens and dorsal striatum, we decided to
consider right and left homologous structures separately,
as we have previously described some degree of left
lateralization of the effects of intranasal OT on rCBF in
men49,63. We used a full factorial linear mixed model,
including diagnosis, treatment and diagnosis × treatment
as fixed effects, participants as a random effect and global
grey-matter CBF as a nuisance variable. All analyses
were implemented in SPSS24 (http://www-01.ibm.com/
software/uk/analytics/spss/). Results are reported at a
level of significance α= 0.05. For the ROI analyses, we
contained the false discovery rate for the number of ROIs
tested at α= 0.05 using the Benjamini–Hochberg
procedure64.
Finally, we conducted a whole-brain exploratory inves-
tigation of treatment, diagnosis and treatment × diagnosis
effects on rCBF, using global grey-matter CBF as a cov-
ariate (see Supplementary Materials for details). We used
cluster-level inference at α= 0.05 using family-wise error
correction for multiple comparisons and a cluster-
forming threshold of P= 0.005 (uncorrected). These sta-
tistical thresholds had been determined a priori based on
our own work investigating the effects of intranasal OT
on rCBF in humans48,49 and are standardly applied in ASL
studies measuring rCBF65–70.
Associations between clinical measures and rCBF in women
with BN/BED and healthy controls
To investigate whether changes in rCBF in women with
BD/BED were related to the severity of clinical sympto-
matology, we correlated the mean rCBF in each of the
four anatomical ROIs where we found significant differ-
ences between the BN/BED and healthy groups with
clinical measures. We focused our analyses on mean rCBF
values extracted from anatomical ROIs to avoid potential
issues of selection bias that might have emerged if we had
based our analyses on rCBF extracted from clusters
showing significant diagnostic group differences in the
whole-brain analyses. As a measure of eating symptom
severity, we used the global EDEQ scores. As patients with
BN/BED score highly on scales measuring anxiety, stress
and depression, and scores on these scales were highly
correlated with each other, we used within-group princi-
pal component analysis (PCA) on these three measures to
obtain a single score reflecting affective/stress symptom
severity. The first principal component accounted for
70.81% and 83.47% of the total variance in the patients
and healthy controls, respectively, and was used in our
analyses to examine the specificity of the association of
rCBF with eating symptom severity.
We estimated partial Pearson’s correlation coefficients
(with bootstrapping—1000 samples) between mean rCBF
and global EDEQ or the first component of the stress,
anxiety and depression scores in each ROI, adjusting for
global CBF and body mass index (BMI). To examine the
specificity of the association between mean rCBF and
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eating symptomatology, we re-estimated the partial
correlations with global EDEQ after including scores on
the first principal component from the PCA on the
stress, anxiety and depression measures. We estimated
these correlations separately in patients and healthy
controls, because group differences in mean scores on
these measures might result in illusory correlations if the
two samples were pooled together71. For completeness,
we then compared these correlations between the patient




As BMI influences perfusion in the brain72 and patients
presented high variability in BMI, we repeated all our
analyses including BMI as a nuisance variable to account
for BMI-related variability in rCBF.
Hormonal contraception
Hormonal contraception can reduce intranasal OT-
induced effects on brain physiology, at least in response to
social stimuli73. As 37.5% of our women were under
hormonal contraception, we repeated all analyses
including hormonal contraception as a nuisance variable.
Diagnostic category, psychiatric comorbidities and current
pharmacological treatment
To disentangle whether the main effect of diagnosis was
driven specifically by BED status, current pharmacological
treatment or the presence of other psychiatric conditions,
we repeated our analyses for the main effect of diagnosis
either excluding the five BED patients or including diag-
nostic category and comorbidities/current treatment as
nuisance variables.
Grey-matter volume
Variations in grey-matter volume (GMV) can be asso-
ciated with local variations in brain tissue metabolic
demand, thereby influencing rCBF74,75. For this reason,
we explored whether the main effects of diagnosis were
related to differences in GMV. For each participant, we
used GM volume probability maps obtained after seg-
mentation of the T1-weighted structural image and the
fslmeants command to estimate mean GMV values in
ROIs based on the clusters where BN/BED patients
showed significant increases in rCBF compared with
controls in the whole-brain analyses (details provided in
Supplementary Materials). We then repeated the whole-
brain analysis testing for the main effects of diagnosis on
rCBF including GMV as a covariate. For completeness, we
also ran an exploratory whole-brain analysis testing for
the main effect of diagnosis on GMV (further details in
Supplementary Material). Our main motivation was to
investigate if clusters showing significant effects of diag-
nosis in rCBF mapped onto brain areas showing sig-
nificant GMV abnormalities, giving us insight in the
interpretation of rCBF abnormalities in BN/BED.
Results
Sample characteristics
Women with BN/BED and healthy controls did not
differ in age, height, BMI, educational level, or hormonal
status (see Table 1). Women with BN/BED had sig-
nificantly higher weight, anxiety, depression and stress
scores, and EDEQ global and subscale scores compared
with healthy women. Women with BN/BED had an
average duration of eating disorder of 10.15 years and the
average age of onset was 15.90 years old. Of the 25 women
with BN/BED, 7 women had a comorbid psychiatric dis-
order. Specifically, five women had comorbid depression,
four women had comorbid generalized anxiety disorder,
four women had borderline personality disorder, one
woman had social anxiety, one woman had obsessive-
compulsive disorder, and one woman had an autism
spectrum disorder. At the time of the study, seven women
were taking an antidepressant, one woman was taking a
mood stabilizer, and one woman was taking an anti-
psychotic drug. Participants with BN/BED reported an
average binge-eating frequency of 14.14 episodes over the
past 28 days (SD= 9.88). The women with BN endorsed
an average frequency of self-induced vomiting equal to
10.40 occasions over the past 28 days (SD= 13.61), an
average laxative abuse frequency of 5.13 occasions over
the past 28 days (SD= 8.35), an average frequency of
“hard exercise intended to control weight or shape” equal
to 7.31 occasions over the past 28 days (SD= 8.57), and 1
participant reported using diuretic pills on 4 occasions
over the past 28 days.
Drug blinding
Participants guessed the drug condition correctly on 57
out of the total 104 visits (54.8% of visits), which was not
significantly different from chance (one-sample binomial
test, z (103)= 57.00, p= 0.377).
Diagnosis, treatment and diagnosis × treatment effects on
resting global CBF
There were no effects of diagnosis, treatment or diag-
nosis × treatment on global grey-matter CBF (Supple-
mentary Fig. S2).
Diagnosis, treatment and diagnosis × treatment effects on
resting rCBF
ROI analyses
Women with BN/BED showed significant rCBF increases
in the medial PFC and OFC ROIs compared with healthy
controls (Supplementary Table S1). These differences did
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not survive correction for the number of total ROIs tested.
Accounting for BMI, women with BN/BED showed sig-
nificant rCBF increases in the medial PFC, OFC, right insula
and ACG gyrus ROIs (Table 2 and Fig. 1), which remained
significant after correcting for multiple testing.
Whole-brain analysis
Exploratory whole-brain analysis revealed rCBF
increases in BN/BED patients in three clusters (Supple-
mentary Fig. S3 and Supplementary Table S2). Two
clusters spanned the inferior/middle temporal gyrus
bilaterally (with a bigger extent at the right lobe) and one
cluster the PFC, medial OFC and ACG bilaterally
(extending more into the left hemisphere). Accounting for
BMI extended the right inferior/middle temporal gyrus
cluster to include the right posterior insula (Fig. 2 and
Supplementary Table S3).
We did not observe any treatment or treatment ×
diagnosis effects.
Table 1 Sociodemographic characteristics.
Variable Healthy controls BN/BED Statistic p
Number 23 25 (20 BN; 5 BED) - -
Age (years) 23.6 (3.79) 25.58 (6.31) T(42)= 1.231 0.225
Height (cm) 162.85 (5.95) 166.38 (7.64) T(46)= 1.684 0.099
Weight (kg) 59.19 (5.51) 67.13 (15.22) T(46)= 2.160 0.037*
BMI (kg/cm2) 22.57 (1.89) 24.19 (5.21) T(46)= 1.407 0.166
RQF (education) 5.31 (1.67) 4.875 (1.75) T(42)= 0.836 0.408
Hormonal status
Contraception 41.7% 32.0%
Follicular phase 29.2% 28.0% χ2 (3)= 5.090 0.165
Luteal phase 8.3% 32.0%
Non-available 20.8% 8%
Duration ED - 10.15 (5.80) - -
Age onset ED - 15.90 (5.07) - -
Comorbidities 0% 28% - -
Medication use 0% 20% - -
Frequency (last 28 days):
Binge eating 14.14 (9.88)
Self-induced vomiting 10.40 (13.61)
Laxative abuse - 5.13 (8.35) - -
Excessive exercising to control shape 7.31 (8.57)
Eating disorder questionnaire (EQED)
Global EQED 1.17 (1.12) 3.91 (1.30) T(43)= 7.794 <0.0001*
Restraint 0.91 (0.90) 3.05 (1.76) T(43)= 5.240 <0.0001*
Eating concern 0.64 (0.86) 3.51 (1.39) T(43)= 8.521 <0.0001*
Weight concern 1.35 (1.52) 4.32 (1.40) T(43)= 7.048 <0.0001*
Shape concern 1.77 (1.57) 4.76 (1.39) T(43)= 6.994 <0.0001*
Depression score 3.05 (4.49) 20.39 (12.31) Mann–Whitney U= 55 <0.0001*
Anxiety score 1.16 (2.52) 11.83 (9.56) Mann–Whitney U= 37 <0.0001*
Stress score 3.68 (5.04) 20.33 (11.69) Mann–Whitney U= 14 <0.0001*
This table shows the sociodemographic characteristics of our cohort of healthy and BN/BED women. Data are presented as mean (SD). The fourth and fifth columns
summarize the statistics corresponding to groups comparison for each variable, when applicable. Statistical significance was set to p < 0.05 and is highlighted with the
symbol *.
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Associations between clinical symptoms and rCBF in
women with BN/BED and healthy controls
We observed significant positive partial correlations
(adjusting for BMI and global CBF) between mean rCBF
extracted from the medial PFC, OFC, ACG and right
insula ROIs and global EDEQ scores, in patients but not
in controls (Fig. 3). Partial correlations between mean
rCBF in these ROIs and global EDEQ were still significant
after additionally accounting for stress, anxiety and
depression (Supplementary Table S4), except for the
Table 2 Effects of diagnosis, treatment and diagnosis × treatment on resting regional cerebral blood flow (rCBF) within
neural circuits relevant for BN/BED (hypothesis-driven analysis).
Region-of-interest Main effect of treatment Main effect of diagnosis Interaction treatment × diagnosis
F P (uncorrected) P (adjusted) F P (uncorrected) P (adjusted) F P (uncorrected) P (adjusted)
VTA 0.727 0.396 1.386 0.296 0.588 0.915 0.003 0.960 0.960
SN 1.400 0.240 1.680 0.027 0.871 1.016 0.006 0.939 1.095
Right Amy 0.154 0.696 1.624 4.231 0.043 0.120 0.008 0.927 1.179
Left amy 0.122 0.727 1.272 3.71×10-4 0.985 0.985 0.282 0.596 1.192
PFC 1.979 0.163 2.282 7.462 0.008 0.028 0.107 0.744 1.302
Orbitofrontal 0.105 0.746 1.160 9.100 0.003 0.042 0.005 0.944 1.016
Insula right 0.058 0.811 1.032 7.854 0.006 0.028 0.970 0.327 1,526
Insula left 0.038 0.846 0.846 1.264 0.264 0.528 0.038 0.846 1.184
HPT 1.315 0.254 1.185 0.254 0.616 0.862 0.076 0.784 1.219
ACG 0.134 0.715 1.430 8.347 0.005 0.035 0.596 0.442 1.031
Dorsal striatum right 0.080 0.778 1.089 2.983 0.088 0.205 0.965 0.329 1.152
Dorsal striatum left 0.054 0.817 0.953 0.019 0.892 0.961 0.985 0.324 2.268
Acc right 0.304 0.583 1.632 0.657 0.420 0.735 0.802 0.373 1.044
Acc left 0.040 0.842 0.907 0.042 0.838 1.067 1.200 0.276 3.864
This table shows the results of a hypothesis-driven investigation of the effects of diagnosis, treatment and diagnosis × treatment on rCBF within 14 anatomical
regions-of-interest suggested to be involved in BN/BED. We tested these effects in a liner mixed model, controlling for global grey-matter cerebral blood flow and BMI.
Statistical significance was set to p < 0.05, after correction for multiple testing with the Benjamini–Hochberg procedure.
Acc accumbens, ACG anterior cingulate gyrus, Amy amygdala, PFC prefrontal cortext, HPT hypothalamus, SN substantia nigra, VTA ventral tegmental area.
Fig. 1 Increases in mean resting regional cerebral blood flow (rCBF) in the anterior cingulate, right insula, orbitofrontal and medial
prefrontal cortices in BN/BED women compared with healthy women (hypothesis-driven analysis). These graphs illustrate the changes in
mean rCBF in BN/BED patients compared with healthy controls for the regions-of-interest where we identified a significant main effect of diagnosis.
For all of these four regions-of-interest, BN/BED women presented higher mean rCBF than healthy women. ACG anterior cingulate gyrus, OFC
orbitofrontal cortex, PFC medial prefrontal cortex. Box plots and violin plots depicting mean rCBF (marginal means) on each region-of-interest for
each diagnosis/treatment groups; middle horizontal lines represent the median; boxes indicate the 25th and 75th percentiles.
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medial PFC ROI for which the correlation was at trend-
level (p= 0.051). However, direct comparisons of these
correlations between the two groups yielded no statisti-




Accounting for use of hormonal contraception pro-
duced no change in our findings (Supplementary Table S5
and Supplementary Fig. S4).
Fig. 2 Increases in resting regional cerebral blood flow (rCBF) in the brain of BN/BED patients (whole-brain analysis). This figure shows the
results of a directed T-contrast analysis at the whole-brain level where we tested for increases (BN/BED > Controls) or decreases (Controls > BN/BED)
in rCBF in patients compared with controls, accounting for global grey-matter cerebral blood flow and BMI. Whole-brain cluster-level inference was
applied at α= 0.05 using family-wise error (FWE) correction for multiple comparisons and a cluster-forming threshold of p= 0.005 (uncorrected).
Images are shown as T-statistic in radiological convention. We did not find any significant cluster BN/BED patients presented lower rCBF than healthy
controls.
Fig. 3 Increases in resting regional cerebral blood flow (rCBF) in the brain of BN/BED patients correlate positively with eating disorder
symptom severity. Left panel: partial Pearson correlations between mean rCBF in each of the four anatomical regions-of-interest where we found
significant differences between the BN/BED and healthy groups, and clinical symptomatology. We used the global EDEQ scores as a measure of
eating disorder symptom severity and the first principal component of the anxiety, stress and depression scores. Partial Pearson correlations were
calculated with bootstrapping (1000 samples) adjusting for global CBF and BMI, separately for controls and patients. In the last columns of each sub-
section, we present the result of the statistical comparison of the correlations between the two groups, as assessed by Fisher’s r-to-z transformation.
Right panel, we present scatter plots depicting the relationship between mean rCBF (marginal scores after regressing out the effects of global CBF
and BMI in the y-axis) and global EDEQ scores (in the x-axis) in each region-of-interest. Statistical significance was set to p < 0.05 and is highlighted
with the symbol *. PFC medial prefrontal cortex, OFC orbitofrontal cortex; ACG anterior cingulate gyrus.
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Diagnostic category, psychiatric comorbidities and current
pharmacological treatment
Excluding the BED patients (Supplementary Fig. S5) or
accounting for diagnostic category (Supplementary Fig.
S6) as a covariate in our model produced did not sub-
stantially change our results. We also did not find any
substantial changes in our results when we accounted for
comorbidities/current drug treatment (Supplementary
Fig. S7).
Is regional GMV associated with the effect of diagnosis in
rCBF?
The main effect of diagnosis in the whole-brain analysis
remained virtually unaltered after accounting for GMV
values in the ROIs based on the clusters where BN/BED
patients showed significant increases in rCBF compared
with controls in the whole-brain analyses (Supplementary
Fig. S8). Furthermore, women with BN/BED showed
lower GMV than controls in two clusters, one spanning
the postcentral and precentral gyri and another the
inferior/middle temporal gyrus, both in the right hemi-
sphere (Supplementary Fig. S9). Interestingly, the right
temporal gyrus cluster partially overlapped with the
cluster showing rCBF increases in women with BD/BED
compared with controls (Supplementary Fig. S9). In the
right temporal gyrus, rCBF and GMV correlated nega-
tively in patients but not in controls (Supplementary Fig.
S10) (BN/BED: r=−0.496, p= 0.012; healthy controls:
r=−0.024, p= 0.913; Groups comparison: z=−1.66,
p= 0.048). We did not identify any area in the brain
where patients presented higher GMV than controls.
Discussion
Using ASL, a highly reproducible and widely available
quantitative MRI technique, we demonstrated, for the first
time, resting hyperperfusion abnormalities in women with
BN/BED, compared with healthy controls, in key neural
circuits implicated in BN/BED psychopathology. Hyper-
perfusion abnormalities in the PFC, medial OFC, ACG
and the right posterior insula were positively and speci-
fically associated with symptom severity as reflected on
the global EDEQ scale in women with BN/BED. However,
a single dose of 40 IU intranasal OT did not restore or
attenuate these perfusion abnormalities at 18–26min post
dosing. Our findings enhance our understanding of rest-
ing brain abnormalities in BN/BED and identify resting
rCBF as a non-invasive potential biomarker for disease-
related changes and treatment monitoring. We discuss
each of our main findings below in turn.
Abnormalities in resting brain perfusion in women with
BN/BED compared with healthy controls
Our hypothesis-driven analyses showed that women
with BN/BED, compared with healthy controls, presented
with increased resting rCBF in the medial PFC, medial
OFC, ACG and the right posterior insula. Exploratory
whole-brain analysis showed further increases in the
inferior/middle/superior temporal cortices in women with
BN/BED. Sensitivity analyses confirmed that these find-
ings were not driven by the inclusion of BED patients and
did not reflect current medication or other psychiatric
comorbidities. In women with BN/BED, estimates of rCBF
in three key areas where we found women with BN/BED
and healthy women to differ in rCBF (medial PFC, ACG
and right insula) correlated positively with global scores
on the EDEQ, even after adjusting for anxiety, depression
and stress, supporting a specific association between rCBF
abnormalities in these regions and the underlying eating
disorder psychopathology. Given the high reliability and
ease of acquisition, our findings suggest that measuring
resting rCBF at BN/BED patients with ASL MRI can offer
a non-invasive in-vivo biomarker of potential value for
understanding disease-related functional changes, posing
minimal demand and no risk on patients. In addition,
future large-scale studies should characterize the sensi-
tivity and specificity of changes in resting rCBF in the
identified brain regions in terms of distinguishing between
patients and controls, or distinguishing between patients
who respond to specific treatments from those who
do not.
We are aware of only three studies examining rCBF in
BN/BED, using SPECT and small sample sizes (7 < n <
14). One study found increased rCBF in the right tem-
poral lobe in response to own body images when a pooled
sample of patients with DSM-IV BN-purging type and
anorexia nervosa-restrictive type were compared with a
pooled sample of healthy controls, patients with DSM-IV
BN-non-purging type and patients with anorexia nervosa-
purging type17. Another study reported increased rCBF in
the left temporal lobe and inferior frontal region bilat-
erally in patients with DSM-III BN before eating16. Finally,
the only study examining patients with BED reported that
obese BED patients, compared with non-obese BED
patients and healthy controls, presented increased rCBF
responses in the frontal and prefrontal cortices in
response to food visual stimuli18. These studies did not
report on rCBF changes at rest, which precludes direct
comparisons between these studies and ours. Never-
theless, we note that the changes in rCBF reported in
these studies are in the same direction and largely overlap
with regions where we found resting hyperperfusion
during BN/BED in our study. Therefore, it is possible that
hyperperfusion in these areas in women with BN/BED
marks a disease-relevant state, which can be captured at
rest and without the need of a specific experimental
manipulation.
The mechanisms behind these increases in resting rCBF
in BN/BED remain unknown. Increases in resting rCBF
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are likely to reflect basal regional hypermetabolism,
potentially associated with increases in resting neural
activity15. We note however that the few small-scale stu-
dies evaluating resting brain glucose metabolism using
PET during BN have generally reported decreases in
global and regional glucose metabolism, including parietal
and anterior frontal hypometabolism76–80. The only
exception is one study that found increased glucose
metabolism in the temporal lobes of patients with BN,
which matches our findings of increased perfusion in
these areas78. BN patients have been reported to present
higher GMV in some areas such as the medial OFC8,
which could account for the increases in rCBF we report
herein; however, we found that this is unlikely to be the
case in our sample. Exploratory whole-brain analysis
showed decreased GMV in the right temporal lobe in BN/
BED compared with controls. This cluster partially over-
lapped with one cluster showing increased rCBF in
patients. GMV was negatively correlated with rCBF in this
area in patients, but not in controls. We speculate that
two possible mechanisms could account for this para-
doxical relationship between rCBF and GMV in the
temporal lobe of patients with BN/BED. One possibility is
that the increases in rCBF we observed in the right tem-
poral lobe might reflect a mechanism of local functional
plasticity in response to GMV loss in this region, which
ultimately may help to maintain temporal lobe function in
patients with BN/BED81,82. Alternatively, it is also con-
ceivable that enduring neural hyperactivity, accompanied
by increases in rCBF, could drive GMV loss due to exci-
totoxicity83. Future longitudinal studies examining how
changes in GMV and rCBF in these brain regions develop
may elucidate these hypotheses.
As our data were acquired at rest, we can only speculate
regarding the specific contribution of the perfusion and
structural abnormalities observed in this study to core
behavioural manifestations in BN/BED. We note that BN/
BED patients have been reported to present with
enhanced sensitivity to the anticipation of food reward/
hedonic value5, which matches the increases in rCBF we
observed in the medial OFC (a key area involved in
reward/outcome value processing84, including the hedo-
nic value of food85). BN, in particular, and, to some extent,
BED have also been associated with continuous feelings of
monitoring of binge-activating stimuli in the environment
and body shape/weight self-judgement, which match our
findings of increased rCBF in the medial PFC and ACC
(two key areas involved in self-monitoring and control
regulation86) in patients. Evidence from lesion studies
have supported a direct implication of the temporal lobe
(predominantly the right lobe) in eating disorders87.
Although the exact mechanisms by which temporal lobe
dysfunction may contribute to eating dysregulation
remain elusive, some studies have implicated the
superior/middle temporal gyri in the brain responses to
palatable food88 and in inhibitory control, including
cognitive control of appetite89—two core elements of
binge eating. Importantly, previous studies have reported
attenuated recruitment of these areas during response
inhibition in both BN90,91 and BED92.
In contrast to our hypotheses, we could not find any
resting rCBF alterations in the ventral or dorsal striatum
in patients with BN/BED. This is surprising, given the
pivotal role of the striatal circuits in cognitive processes
known to be disrupted in BN/BED (such as incentive and
habitual behaviours93, impulsivity94 and self-regulation95)
and previous neuroimaging studies demonstrating func-
tional and structural abnormalities in these areas (see
refs. 7,8 for detailed reviews). It is possible that while
disrupted rCBF in the striatum in BN/BED may not
manifest at rest, alterations may become evident in con-
dition engaging this region, such as the anticipation or
valuation of hedonic stimuli (e.g., food).
Does intranasal OT restore rCBF abnormalities in women
with BN/BED?
The lack of treatment or treatment × diagnosis effects
does not support a normalizing effect of 40 IU intranasal
OT on resting rCBF abnormalities in women with BN/
BED 18–26 min post dosing. A number of reasons might
explain the lack of effects of intranasal OT on rCBF in this
study. First, it is possible that we may have missed the
active time-window for intranasal OT treatment effects in
women with BN/BED. We have previously mapped
intranasal OT-induced effects on brain perfusion in men
and demonstrated that while 40 IU intranasal OT can
induce changes in resting perfusion as early as 15 min
post dosing (earlier intervals have not been sampled), the
effects do vary as a function of method of administration,
dose and the latency of the sampling interval post dos-
ing48. However, we are still lacking an in-depth pharma-
codynamics investigation of OT-induced changes in rCBF
in women. Previous studies have shown that the effects of
the administration of the same dose of intranasal OT to
men and women can result in different effects on beha-
viour and brain function96–100. A recent study has shown
that differences in the effects of a range of doses of
intranasal OT on brain responses to happy and fearful
faces between men and women do not simply reflect
differences in dose sensitivity, but rather gender-specific
effects101. Therefore, although we have informed this
current study based on our in-depth characterizations of
the pharmacodynamics of intranasal OT in men, it is
possible that crucial differences exist in the spatio-
temporal pattern of rCBF changes after intranasal OT
between genders. Future studies should systematically
investigate the potential effects of these factors, including
a comparison of acute vs. chronic regimens of
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administration, characterization of rCBF changes over an
extended period of time and dose–response studies in
women. Second, hormonal contraception has been shown
to blunt responses to intranasal OT in women73.
Although accounting for contraception in our analyses
produced virtually no change in our results, it is plausible
that OT might have exerted an effect on rCBF in our
sample in the absence of hormonal contraception. Finally,
while we could not detect any significant treatment effects
on rCBF in women with or without BN/BED at rest in this
study, we cannot exclude that significant effects of intra-
nasal OT might emerge during targeted experimental
challenges, such as exposure to food cues102 or stress103.
Indeed, we have recently shown that a divided dose of
intranasal OT (64 IU) modulates risk-taking behaviour in
women with BN/BED45 and increases vigilance towards
food, vs. neutral, images in a dot probe task in both
women with and without BN/BED46 (but does not affect
eating behaviour or stress response47), using the same
sample.
Limitations
One limitation of our study is that we only included
women. Our findings should thus not be extrapolated to
men with BN/BED. Second, we could only enrol a small
number of BED patients, which did not allow us to isolate
effects related to diagnostic category. Third, although we
have asked subjects to eat 2.5 h before our experimental
sessions in order to minimize the effects of baseline
hunger, we did not standardized the amount or type of
food consumed, which may have introduced some noise
in our data. Lastly, 20% of our BN/BED sample had other
psychiatric comorbidities and 28% were under current
pharmacological treatment, respectively, which may have
confounded our results. We have investigated the impact
of such factors in a sensitivity analysis where we repeated
our main analyses including current treatment and
comorbidities as a nuisance variable. Although our find-
ings remained largely unaltered, future replication in
samples of women with BN/BED and without these
confounds would be beneficial.
Conclusions
BN/BED in women is accompanied by increased resting
perfusion in key brain areas potentially associated with the
underlying eating psychopathology. Intranasal OT did not
attenuate or restore these abnormalities, at least for the
specific dose and post-dosing interval examined. Future
studies examining a more comprehensive range of doses,
time-windows and schemes of administration will be
needed before we can ascertain the therapeutic value of
intranasal OT in improving resting rCBF disturbances in
women with BN/BED. Given the high reliability and ease
of acquisition, measuring resting rCBF at BN/BED
patients with ASL MRI offers a promising non-invasive
in-vivo biomarker of functional changes in these patients,
with potential implications for diagnosis and treatment
monitoring.
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